Logo image of IPHA

INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:IPHA - US45781K2042 - ADR

1.75 USD
-0.01 (-0.57%)
Last: 12/19/2025, 8:00:02 PM
1.5999 USD
-0.15 (-8.58%)
After Hours: 12/19/2025, 8:00:02 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IPHA. IPHA was compared to 530 industry peers in the Biotechnology industry. IPHA may be in some trouble as it scores bad on both profitability and health. IPHA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

IPHA had negative earnings in the past year.
In the past year IPHA has reported a negative cash flow from operations.
In the past 5 years IPHA always reported negative net income.
In the past 5 years IPHA always reported negative operating cash flow.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of -49.46%, IPHA is in line with its industry, outperforming 50.19% of the companies in the same industry.
IPHA has a worse Return On Equity (-894.94%) than 80.26% of its industry peers.
Industry RankSector Rank
ROA -49.46%
ROE -894.94%
ROIC N/A
ROA(3y)-25.47%
ROA(5y)-23.4%
ROE(3y)-225.59%
ROE(5y)-153.39%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

With a decent Gross Margin value of 49.52%, IPHA is doing good in the industry, outperforming 75.56% of the companies in the same industry.
In the last couple of years the Gross Margin of IPHA has declined.
IPHA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPHA has been increased compared to 1 year ago.
IPHA has more shares outstanding than it did 5 years ago.
IPHA has a worse debt/assets ratio than last year.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

Based on the Altman-Z score of -6.43, we must say that IPHA is in the distress zone and has some risk of bankruptcy.
IPHA has a Altman-Z score of -6.43. This is in the lower half of the industry: IPHA underperforms 65.98% of its industry peers.
A Debt/Equity ratio of 11.63 is on the high side and indicates that IPHA has dependencies on debt financing.
IPHA has a Debt to Equity ratio of 11.63. This is amonst the worse of the industry: IPHA underperforms 82.89% of its industry peers.
Industry RankSector Rank
Debt/Equity 11.63
Debt/FCF N/A
Altman-Z -6.43
ROIC/WACCN/A
WACC6.74%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

IPHA has a Current Ratio of 2.24. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.24, IPHA is not doing good in the industry: 74.44% of the companies in the same industry are doing better.
A Quick Ratio of 2.24 indicates that IPHA has no problem at all paying its short term obligations.
With a Quick ratio value of 2.24, IPHA is not doing good in the industry: 72.18% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.24
Quick Ratio 2.24
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

3

3. Growth

3.1 Past

IPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -29.32%.
The Revenue for IPHA has decreased by -75.86% in the past year. This is quite bad
Measured over the past years, IPHA shows a very negative growth in Revenue. The Revenue has been decreasing by -28.80% on average per year.
EPS 1Y (TTM)-29.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%

3.2 Future

IPHA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -3.32% yearly.
IPHA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.06% yearly.
EPS Next Y-32.84%
EPS Next 2Y-10.27%
EPS Next 3Y-3.32%
EPS Next 5YN/A
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y43.06%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IPHA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPHA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

IPHA's earnings are expected to decrease with -3.32% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.27%
EPS Next 3Y-3.32%

More info and screens

0

5. Dividend

5.1 Amount

IPHA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (12/19/2025, 8:00:02 PM)

After market: 1.5999 -0.15 (-8.58%)

1.75

-0.01 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-26 2026-03-26/amc
Inst Owners10.45%
Inst Owner Change-18.25%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap161.29M
Revenue(TTM)6.00M
Net Income(TTM)-46.00M
Analysts80
Price Target5.68 (224.57%)
Short Float %0.37%
Short Ratio1.01
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.17%
PT rev (3m)-14.92%
EPS NQ rev (1m)-0.07%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.07%
EPS NY rev (3m)-258.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-72.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.95
P/FCF N/A
P/OCF N/A
P/B 27.54
P/tB 27.54
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.55
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.52
OCFYN/A
SpS0.08
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.46%
ROE -894.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.52%
FCFM N/A
ROA(3y)-25.47%
ROA(5y)-23.4%
ROE(3y)-225.59%
ROE(5y)-153.39%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score1
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 11.63
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.9%
Cap/Sales 2.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.24
Quick Ratio 2.24
Altman-Z -6.43
F-Score1
WACC6.74%
ROIC/WACCN/A
Cap/Depr(3y)22.75%
Cap/Depr(5y)23.43%
Cap/Sales(3y)3.29%
Cap/Sales(5y)8.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-29.32%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.35%
EPS Next Y-32.84%
EPS Next 2Y-10.27%
EPS Next 3Y-3.32%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-26.21%
Revenue Next 2Y3.05%
Revenue Next 3Y2.41%
Revenue Next 5Y43.06%
EBIT growth 1Y-30.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.86%
EBIT Next 3Y68.81%
EBIT Next 5YN/A
FCF growth 1Y-26.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.51%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA-SPONS ADR / IPHA FAQ

What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IPHA.


What is the valuation status for IPHA stock?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.


What is the profitability of IPHA stock?

INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.


What is the financial health of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 2 / 10.